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The complete eradication of cholera is an unachievable goal because it is now 
firmly established that there are environmental reservoirs for Vibrio cholerae. Although 
there are effective treatments for this disease, they are expensive and impractical in time 
of epidemic. All these points lead to the fact that the development of a safe, cheap and 
efficient vaccine is probably the best solution to the problem. A variety of strategies 
have been employed to create better vaccines against cholera but these traditional 
vaccines produced still suffer from a number of inherent drawbacks. Therefore, a new 
type of cholera vaccine is being proposed which may retain all the positive aspects of the 
existing vaccines while avoiding their shortcomings. It belongs to a new generation of 
vaccines termed DNA vaccines. The development of this vaccine has been 
revolutionized by the finding that antigen-encoding DNA plasmids can be used to 
induce cellular and humoral immune responses against immunogenic determinant. In 
this study, the focus is on the ctxB gene, the gene encoding the B subunit cholera toxin 
as a potential candidate for a vaccine against cholera. The ctxB gene is required for the 
binding of the Cholera Toxin (CT) to the eukaryotic cell and facilitates the entry of the 
active toxin (CTXA) into the host cell which in turn, produces the profuse diarrheal 
symptom. The ctxB gene has been successfully cloned in an expression vector, pVax, 
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and proven to be in the correct orientation by PCR and sequencing. Subsequently, the B 
subunit toxin was expressed in vitro in the p V ax! ctxB using COS-7 cells by a non­
liposomal lipid Effectene™ (Qiagen) method, 90 hours post transfection. The results 
from the studies indicate that the DNA plasmid carrying the ctxB gene (pVaxJctxB) was 
able to use the cell's transcription and translation machineries to produce the required 
antigen. 
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Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
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Eradikasi taun adalah masalah yang tidak dapat diselesaikan kerana 
adanya penyimpanan alam sekeliling bakteria Vibrio cholerae. Walaupun pembatan 
yang efektif telah dihasilkan untuk penyakit ini, ianya adalah mahal dan tidak praktikal 
pada masa epidemik. Oleh kerana itu, vaksin yang selamat, murah dan mujarab adalah 
perlu untuk mengatasi masalah tersebut. Pelbagai cara telah digunakan untuk mencipta 
vaksin yang lebih baik tetapi vaksin-vaksin tersebut masih lagi mempunyai kekurangan. 
Oleh itu, vaksin taun jenis bam telah dicadangkan dimana segala aspek-aspek positif 
vaksin yang telah ada dikekalkan manakala kekurangannya diketepikan. Vaksin 
generasi bam ini dipanggil vaksin DNA. Penciptaan vaksin ini telah dipercepatkan 
dengan penemuan dimana plasmid DNA yang mengandungi antigen boleh 
mengakibatkan tindak balas imuniti "cellular" dan "humoral". Dalam kajian ini, gen 
ctxB, iaitu gen untuk toksin B kolera, menjadi fokus sebagai calon yang sesuai untuk 
penciptaan vaksin DNA untuk mengatasi taun. Gen ctxB diperlukan untuk pertambatan 
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toksin kolera (CT) kepada sel "eukaryote" dan menyebabkan kemasukan toksin A 
(CTXA) yang lebih aktif ke dalam sel lalu menghasilkan simptom cirit-birit taun. Gen 
ctxB ini telah bejaya diklon ke dalam p Vax dan dibuktikan berada pada kedudukan yang 
betul melalui analisis Rantaian Reaksi Polimerase dan penjujukan DNA. Kemudian, 
toksin B telah diekspresikan daripada pVax/ctxB dengan menggunakan sel COS-7 dan 
kaedah lipid bukan liposom Effectene™ (Qiagen), 90 jam selepas transfeksi. Keputusan 
ujikaji ini menunjukkan bahawa plasmid yang mengandungi gen ctxB tersebut 
(pVaxlctxB) boleh melalui proses transkripsi dan translasi untuk menghasilkan antigen 
yang dikehendaki. 
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CHAPTERl 
INTRODUCTION 
In 1854, when a cholera epidemic erupted in India and traveled west to the town 
of London, a renowned anesthesiologist, Dr. John Snow dedicated himself to discover 
the source of the devastating disease. His work took him from the upper-class residence 
to the poor, marking the house of the people stroked by the disease on a map. Noticing 
that the cases centered on a public water pump at Broad Street, South London, Snow 
persuaded the authorities to remove the pump handle which forced the residents to go 
elsewhere for a source of drinking water. As soon as the water from the well was no 
longer being used, the cases of cholera declined dramatically. 
Dr. John Snow's work earned him a legendary status in the field of public health 
and epidemiology. His essay titled "On the Mode of Communication of Cholera" 
published in 1855 (1), was the first treatise in which he set forth his observations and 
recommendations on instances of cholera and measures to put this disease arrest. 
Yet, 145 years later, we are still plagued by this dreadful disease. A half million 
cases have been reported to the World Health Organization (WHO) in the last two years 
with 20,000 deaths. The reported overall case-fatality rate (CFR) for 1999 has remained 
stable at 3.6%, in which the Asian continent showed a 61 % increase compared to 1998. 
To make matters worse, the number of deaths notified to WHO due to this disease has 
also doubled. As for Malaysia, a 535 case-fatality rate was reported to WHO in 1999 
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with no death (2). Although there is no mortality, this number signifies that cholera is 
one of the major gastrointestinal diseases in this country. 
The significance of this disease has prompted scientists to sequence the whole 
genome of Vibrio cholerae, the aetiological agent for cholera. The complete sequence 
of both the chromosomes of the cholera pathogen has been published recently (3) and it 
is hoped that this knowledge will help us understand the complete molecular description 
of this pathogen and formulate newer strategies to eradicate this disease. 
Despite the suggestion by Dr. John Snow, it is clear that trying to provide 
uncontaminated water supply and educating the public on the preventive measures only 
are not enough to control the transmission of cholera, especially in the developing world. 
Even though we now have better treatments for cholera, such as antibiotics and oral 
rehydration salts, compared to during the time of Dr. Snow's, these remedies are not 
practical. Antibiotics, for instance, are quite costly and their excessive use can promote 
the development of a new antibiotic resistance bacterial strain, which will defeat the 
purpose of the treatment. 
The best alternative is to provide a cholera vaccine that will immunize the public 
before an outbreak occurs. Several cholera vaccines have been created, yet they are not 
effective and potent enough. It has been noted by WHO that these traditional vaccines 
evoke protection against illness in only about 50% of individuals immunized and they 
last only 3-6 months, and are even less effective in younger children (4). Clearly, these 
traditional vaccines have not delivered the response we require. 
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Fortunately, due to the unrnet needs of old and new epidemics of infectious 
diseases, as well as the advent of molecular biology, a new era of vaccinology has been 
stimulated. This novel approach employs plasmid DNA, engineered to express one or 
more genes of the pathogen in mammalian cells. The proteins expressed lead to a 
stronger and persistent cell-mediated and humoral immune response compared to the 
conventional and the recombinant vaccines. This unique approach to immunization, 
termed DNA vaccination, may overcome deficits of the traditional antigen-based 
methods and provide safe and effective prophylactic and therapeutic vaccines. Since it is 
easy to produce in mass once it has been manufactured, this DNA vaccine will be much 
cheaper than the conventional vaccine. 
In this study, we manipulated and used the knowledge in genetic engineering, 
recombinant DNA technology and immunology to design a DNA vaccine against the 
disease cholera. The vaccine candidate consists of the ctxB gene, the gene encoding the 
B subunit enterotoxin of the Vibrio cholera. It is hoped that the B subunit of this cholera 
toxin when expressed will establish adequate levels of antibody and a primed population 
of cells, which would rapidly expand in numbers upon second contact with the "real" 
pathogen. 
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Objectives 
Thus, the objectives of this study are: (1) to identify and amplify the DNA 
sequence of Vibrio cholera B subunit cholera toxin from local cholera strains, (2) to 
confirm the DNA sequence by probing with an identified target DNA sequence 
(oligonucleotide) and by sequencing the amplified DNA product, (3) to clone the 
sequence in an appropriate mammalian expression vaccine vector, and finally (4) to 
assess the expression of the product in mammalian cell culture. 
CHAPTER II 
LITERATURE REVIEW 
Cholera 
The History 
Cholera has afflicted humans for more than 2,000 years. It has smoldered in an 
endemic fashion on the Indian subcontinent for centuries. The symptoms were 
mentioned as long ago as Hippocrates and even earlier in Sanskrit writings. Epidemic 
cholera was described in 1563 by Garcia del Huerto, a Portuguese physician at Goa, 
India. The mode of transmission of cholera by water was proven in 1849 by John Snow, 
a London physician. In 1883, Robert Koch successfully isolated the cholera vibrio from 
the intestinal discharges of cholera patients and proved conclusively that it was the agent 
of the disease. 
The first long-distance spread of cholera to Europe and the Americas began in 
1817 and by the early 20th century, six waves of cholera had spread across the world in 
devastating epidemic fashion. Since then, until the 1960s, the distribution of the disease 
contracted, remaining present only in southern Asia. In 1961, the "El Tor" biotype 
(distinguished from Classic biotypes by the production of hemolysins) re-emerged to 
produce a major epidemic in the Philippines and to initiate a seventh global pandemic. 
